MAP2K2

Overview

MAP2K2 (MEK2) is a MAPK kinase paralog of MAP2K1. In CLL it was nominated as a novel driver via 3-D mutation clustering.

Alterations observed in the corpus

  • Novel CLL driver identified via CLUMPS 3-D clustering; 3 mutations in the kinase domain, inferred to activate ERK signaling analogous to MAP2K1 PMID:35927489.
  • Novel RAF-inhibitor resistance gene; acquired mutations V35M, L46F, C125S, N126D identified in BRAF V600-mutant melanoma patients; C125S confers >100-fold cross-resistance to both RAF and MEK inhibition PMID:24265153
  • MAP2K2 (MEK2) listed as part of the MAPK pathway landscape in cutaneous melanoma (TCGA 333-sample cohort); pathway members include BRAF, NRAS, NF1, MAP2K1, and RAC1 PMID:26091043

Cancer types (linked)

Co-occurrence and mutual exclusivity

  • None reported.

Therapeutic relevance

  • None directly tested; authors suggest activated ERK signaling as the functional consequence PMID:35927489.

Open questions

  • Functional validation of MAP2K2 as a CLL driver is deferred to future work PMID:35927489.

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:24265153

This page was processed by crosslinker on 2026-05-14. - PMID:26091043

This page was processed by crosslinker on 2026-05-14.